Shares of Biogen (BIIB) are up $7.51, or 4% to $182.81 in pre-market trading after Novo Nordisk (NVO) announced that the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease did not confirm superiority of semaglutide versus placebo in the reduction of progression of Alzheimer’s disease.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen, Dayra Therapeutics enter research collaboration
- Biogen price target raised to $157 from $118 at Piper Sandler
- Biogen, Stoke Therapeutics announce publication of data from BUTTERFLY study
- Stoke Therapeutics, Biogen publish final data from BUTTERFLY study
- Biogen says CHMP adopts positive opinion on high dose regimen of nusinersen